Acute Coronary Syndrome and Myocardial Infarction
Corflow Therapeutics AG focuses on ST-elevated myocardial infarction and related acute coronary syndrome presentations, with attention to patients experiencing microvascular obstruction after coronary reperfusion.
- STEMI
- STEACS
- Microvascular obstruction
The sponsor’s clinical interest centers on cardiovascular injury linked to impaired microcirculation and the treatment of coronary complications following acute ischemic events.
Intracoronary Therapeutic Delivery
Its research activity includes intracoronary infusion approaches designed to deliver therapeutic agents directly into the coronary circulation, with emphasis on localized treatment of damaged myocardial tissue.
- Coronary infusion
- Targeted cardiac delivery
- Endovascular intervention
The therapeutic focus extends to delivery platforms intended to support treatment of coronary microvascular injury in the setting of acute infarction.
Microvascular Injury and Cardiac Tissue Protection
The sponsor is involved in research addressing microvascular injury, myocardial perfusion impairment, and markers associated with recovery of injured cardiac tissue after reperfusion.
- Microvascular perfusion
- Reperfusion injury
- Myocardial salvage
These interests align with clinical efforts to assess injury patterns and treatment response in patients with coronary flow disturbance.
Biomarkers of Treatment Response
Corflow Therapeutics AG also explores markers of efficacy relevant to coronary intervention and myocardial recovery, including indicators of response to locally delivered therapeutic agents.
- Efficacy biomarkers
- Treatment response markers
- Cardiovascular imaging endpoints
These areas support evaluation of therapeutic impact in acute coronary settings where microvascular damage is a central concern.
